TYK2 kinase activity is required for functional type I interferon responses in Vivo

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Prchal Murphy, Michaela ^a   Semper, Christian ^a   Lassnig, Caroline ^a   Wallner, Barbara ^a   Gausterer, Christian ^a   Teppner Klymiuk, Ingeborg ^a   Kobolak, Julianna ^b   Müller, Simone ^a   Kolbe, Thomas ^a,c   Karaghiosoff, Marina ^a   Dinnyés, Andras ^b,d   Rülicke, Thomas ^a   Leitner, Nicole R ^a   Strobl, Birgit ^a   Müller, Mathias ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b SZENT ISTVÁN UNIVERSITY   (Hungary)

^c UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^d BIOTALENTUM LTD   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; JANUS KINASE; PROTEIN KINASE TYK2; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; GENE LOCUS; GENE TARGETING; HOST RESISTANCE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; INNATE IMMUNITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIRUS RESISTANCE;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; ENZYME ACTIVATION; GENE ORDER; GENE TARGETING; GENETIC PREDISPOSITION TO DISEASE; IMMUNITY, INNATE; INTERFERON TYPE I; INTERFERON-BETA; JANUS KINASES; MICE; MICE, KNOCKOUT; MUTATION; ORGAN SPECIFICITY; PROTEIN STABILITY; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TYK2 KINASE; VIRUS DISEASES;

EID: 84862507099     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039141     Document Type: Article

References (62)

1. Wilks AF, (2008) The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol 19: 319-328.
2. Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, et al (2004) The Janus kinases (Jaks). Genome Biol 5: 253.
3. Darnell JE Jr, Kerr IM, Stark GR, (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421.
4. Velazquez L, Fellous M, Stark GR, Pellegrini S, (1992) A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70: 313-322.
5. Strobl B, Stoiber D, Sexl V, Müller M, (2011) Tyrosine kinase 2 (Tyk2) in cytokine signalling and host immunity. Front Biosci 17: 3224-3232.
6. Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, et al. (2000) Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13: 549-560.
7. Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, et al. (2006) Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 26: 804-819.
8. Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, et al. (2000) Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13: 561-571.
9. Shaw MH, Boyartchuk V, Wong S, Karaghiosoff M, Ragimbeau J, et al. (2003) A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci U S A 100: 11594-11599.
10. Uze G, Schreiber G, Piehler J, Pellegrini S, (2007) The receptor of the type I interferon family. Curr Top Microbiol Immunol 316: 71-95.
11. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, et al. (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25: 745-755.
12. Schindler C, Plumlee C, (2008) Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol 19: 311-318.
13. van Boxel-Dezaire AH, Rani MR, Stark GR, (2006) Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25: 361-372.
14. Gough DJ, Levy DE, Johnstone RW, Clarke CJ, (2008) IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev 19: 383-394.
15. Platanias LC, (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5: 375-386.
16. Haan C, Kreis S, Margue C, Behrmann I, (2006) Jaks and cytokine receptors-an intimate relationship. Biochem Pharmacol 72: 1538-1546.
17. Haan C, Behrmann I, Haan S, (2010) Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med 14: 504-527.
18. Hanks SK, Quinn AM, (1991) Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol 200: 38-62.
19. Gauzzi MC, Velazquez L, McKendry R, Mogensen KE, Fellous M, et al. (1996) Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J Biol Chem 271: 20494-20500.
20. Krishnan K, Pine R, Krolewski JJ, (1997) Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner. Eur J Biochem 247: 298-305.
21. Velazquez L, Mogensen KE, Barbieri G, Fellous M, Uze G, et al. (1995) Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction. J Biol Chem 270: 3327-3334.
22. Yeh TC, Dondi E, Uze G, Pellegrini S, (2000) A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc Natl Acad Sci U S A 97: 8991-8996.
23. Staerk J, Kallin A, Demoulin JB, Vainchenker W, Constantinescu SN, (2005) JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem 280: 41893-41899.
24. Gakovic M, Ragimbeau J, Francois V, Constantinescu SN, Pellegrini S, (2008) The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor. J Biol Chem 283: 18522-18529.
25. Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, et al. (2003) The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J 22: 537-547.
26. Gauzzi MC, Barbieri G, Richter MF, Uze G, Ling L, et al. (1997) The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. Proc Natl Acad Sci U S A 94: 11839-11844.
27. Huang LJ, Constantinescu SN, Lodish HF, (2001) The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 8: 1327-1338.
28. Radtke S, Hermanns HM, Haan C, Schmitz-Van De Leur H, Gascan H, et al. (2002) Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression. J Biol Chem 277: 11297-11305.
29. Potla R, Koeck T, Wegrzyn J, Cherukuri S, Shimoda K, et al. (2006) Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol Cell Biol 26: 8562-8571.
30. Rani MR, Leaman DW, Han Y, Leung S, Croze E, et al. (1999) Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem 274: 32507-32511.
31. Briscoe J, Rogers NC, Witthuhn BA, Watling D, Harpur AG, et al. (1996) Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. EMBO J 15: 799-809.
32. Mamo S, Kobolak J, Boríró I, Bíró T, Bock I, et al. (2011) Gene targeting and Calcium handling efficiences in mouse embryonic stem cell lines. World J Stem Cells 26: 127-140.
33. Schwenk F, Baron U, Rajewsky K, (1995) A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 23: 5080-5081.
34. Teppner I, Aigner B, Schreiner E, Müller M, Windisch M, (2004) Polymorphic microsatellite markers in the outbred CFW and ICR stocks for the generation of speed congenic mice on C57BL/6 background. Lab Anim 38: 406-412.
35. Finley D, (2009) Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 78: 477-513.
36. Yang Z, Klionsky DJ, (2010) Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 22: 124-131.
37. Wu WT, Chi KH, Ho FM, Tsao WC, Lin WW, (2004) Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB (nuclear factor kappaB) inhibition. Biochem J 379: 587-593.
38. Lamark T, Johansen T, (2010) Autophagy: links with the proteasome. Curr Opin Cell Biol 22: 192-198.
39. Huss M, Wieczorek H, (2009) Inhibitors of V-ATPases: old and new players. J Exp Biol 212: 341-346.
40. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19: 5720-5728.
41. Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, et al. (1995) A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J 14: 1421-1429.
42. Strobl B, Bubic I, Bruns U, Steinborn R, Lajko R, et al. (2005) Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J Immunol 175: 4000-4008.
43. Vogl C, Flatt T, Fuhrmann B, Hofmann E, Wallner B, et al. (2010) Transcriptome analysis reveals a major impact of tyrosine kinase 2 (Tyk2) on the expression of interferon responsive and metabolic genes. BMC Genomics 11: 199.
44. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
45. Schwarz EM, Badorff C, Hiura TS, Wessely R, Badorff A, et al. (1998) NF-kappaB-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice. J Virol 72: 5654-5660.
46. Detje CN, Meyer T, Schmidt H, Kreuz D, Rose JK, et al. (2009) Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol 182: 2297-2304.
47. Frenzel K, Wallace TA, McDoom I, Xiao HD, Capecchi MR, et al. (2006) A functional Jak2 tyrosine kinase domain is essential for mouse development. Exp Cell Res 312: 2735-2744.
48. Rani MR, Gauzzi C, Pellegrini S, Fish EN, Wei T, et al. (1999) Induction of beta-R1/I-TAC by interferon-beta requires catalytically active TYK2. J Biol Chem 274: 1891-1897.
49. Rani MR, Pandalai S, Shrock J, Almasan A, Ransohoff RM, (2007) Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-beta. J Interferon Cytokine Res 27: 767-779.
50. Croker BA, Kiu H, Nicholson SE, (2008) SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19: 414-422.
51. Yoshimura A, Naka T, Kubo M, (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7: 454-465.
52. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, et al. (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-929.
53. Narazaki M, Fujimoto M, Matsumoto T, Morita Y, Saito H, et al. (1998) Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci U S A 95: 13130-13134.
54. Piganis RA, de Weerd NA, Gould JA, Schindler CW, Mansell A, et al. (2011) Suppressor of cytokine signaling (SOCS)1 inhibits type I interferon (IFN) signaling via the IFNAR1 associated tyrosine kinase, Tyk2. J Biol Chem 286: 33811-33818.
55. Sakamoto H, Yasukawa H, Masuhara M, Tanimura S, Sasaki A, et al. (1998) A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood 92: 1668-1676.
56. Ren J, Kolli D, Liu T, Xu R, Garofalo RP, et al. (2011) Human Metapneumovirus Inhibits IFN-beta Signaling by Downregulating Jak1 and Tyk2 Cellular Levels. PLoS One 6: e24496.
57. Zurney J, Howard KE, Sherry B, (2007) Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol 81: 13668-13680.
58. Chrencik JE, Patny A, Leung IK, Korniski B, Emmons TL, et al. (2010) Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol 400: 413-433.
59. Tsui V, Gibbons P, Ultsch M, Mortara K, Chang C, et al. (2011) A new regulatory switch in a JAK protein kinase. Proteins 79: 393-401.
60. Kovarik P, Mangold M, Ramsauer K, Heidari H, Steinborn R, et al. (2001) Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. EMBO J 20: 91-100.
61. Hanks M, Wurst W, Anson-Cartwright L, Auerbach AB, Joyner AL, (1995) Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2. Science 269: 679-682.
62. Karaghiosoff M, Steinborn R, Kovarik P, Kriegshauser G, Baccarini M, et al. (2003) Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 4: 471-477.